Navigation Links
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
Date:2/6/2009

t." Findings presented in this poster support the evaluation of BCX-4208 in the treatment of not only T-cell mediated diseases, but also B-cell mediated diseases.

Corporate Developments

  • Stanley C. Erck was appointed to BioCryst's Board of Directors in December 2008. Mr. Erck joined the Company's Board with over 20 years of experience in the biotechnology industry, most recently having served as President and Chief Executive Officer of Iomai Corp. At Iomai, he led the company through an initial public offering, a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. In addition to BioCryst, Mr. Erck currently serves on the Board of Directors of both MacCyte and MdBio Foundation.

Conference Call and Web Cast

BioCryst's management team will host a conference call and Web cast on Friday, February 6, 2009, at 8:30 a.m. Eastern Time to discuss the financial results and recent corporate developments. To participate in the conference call, please dial 1-800-860-2442 (United States) or 1-412-858-4600 (International). No passcode is needed for the call. The Web cast can be accessed by logging onto http://www.biocryst.com. Please connect to the Web site at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About BioCryst

BioCryst is a biopharmaceutical company that has developed a deep pipeline of novel therapeutics targeting major illnesses by employing crystallography and structure-based drug design. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. In addition, the Company has a pre-clinica
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a ... today announced that it has received notification from The ... been approved for listing on the NASDAQ Global Market. ... 2009 on NASDAQ at market open under the symbol ...
... 6 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a ... today announced it has received US$2,500,000 from MannKind ... the option agreement and issuance of 2,400,000 units ... The transaction provides MannKind with the option to ...
... Star Scientific (Nasdaq :STSI) announced today that its ... its Star Tobacco, Inc. subsidiary, recently completed a ... dissolvable smokeless tobacco to relieve cigarette withdrawal symptoms ... (NRT). The study, which included 49 cigarette smokers, ...
Cached Biology Technology:BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market 2SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin 2SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin 3Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 2Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 3Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 4
(Date:4/15/2014)... Biologists at UC San Diego have succeeded in ... hormone responsible for growth and resistance to drought. ... studies to determine how the hormone helps plants ... by the continuing increase in the atmosphere,s carbon ... achievement appears in the April 15 issue of ...
(Date:4/15/2014)... Looking at the question of how social behavior has ... universities in Mainz and Basel have gained new insights ... simply compete for food. Rather the siblings share what ... absent," explained Dr. Jol Meunier of the Evolutionary Biology ... University of Mainz (JGU). The team of biologists from ...
(Date:4/15/2014)... (April 15, 2014) The American Association of Anatomists ... All awards will be presented during the Closing ... Hotel on Tuesday, April 29th at 7:30 p.m. during ... , The 2014 award winners are: , ... PhD, of the Icahn School of Medicine at Mount ...
Breaking Biology News(10 mins):Biologists develop nanosensors to visualize movements and distribution of plant hormone 2Sibling cooperation in earwig families gives clues to early evolution of social behavior 2American Association of Anatomists 2014 award winners 2
... Spanish scientists have analysed the temperature and salt levels of ... the evolution of each variable. Their research shows that, since ... hotter and saltier, and that, since the 1990s, this process ... deep layer of the Western Mediterranean increases by 0.002C, and ...
... Miami (UM) has been selected to receive a $1.4 ... to strengthen the UM undergraduate science education program. The ... will use the resources to help attract first-generation college ... sciences to pursue careers in science. , "HHMI ...
... of Oxford and Royal Holloway University of London have discovered that ... works best if applied to young plants and is enhanced by ... (20 May) in the open-access journal PLoS Pathogens . ... is a common method for controlling a variety of insect ...
Cached Biology News:Temperature and salt levels of the Western Mediterranean are on the increase 2UM receives 5th consecutive Howard Hughes Medical Institute grant for science education 2Study uncovers optimal ecology of bioinsecticide 2
...
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: